Price$126.01+0.26 (+0.21%)
07:30 PM07:45 PM
News · 26 weeks45-47%
2026-02-012026-07-26
Mix3390d
- Insider23(70%)
- SEC Filings4(12%)
- Other3(9%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- INSIDEROfficer Johnson Nancy Joann sold $1,821,628 worth of shares (14,199 units at $128.29) as part of a pre-agreed trading plan, decreasing direct ownership by 67% to 6,900 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- PRBillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for NorthstarRenowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne to advance Northstar's role in guiding real treatment decisionsMENLO PARK, Calif., July 20, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Ethan Dmitrovsky, MD, one of the most accomplished and influential physician leaders in oncology, as Chief Medical Officer, Oncology. Dr. Dmitrovsky will lead medical strategy for BillionToOne's Northstar liquid biopsy portfolio
- INSIDERSVP of Laboratory Operations Ten Bosch John Roderick sold $533,330 worth of shares (4,251 units at $125.46) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 29,301 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Technology Officer Tsao David exercised 20,000 shares at a strike of $2.80 and sold $2,497,698 worth of shares (20,000 units at $124.88) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- PRBillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, August 5, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested
- INSIDERChairman and CEO Atay Oguzhan exercised 12,500 shares at a strike of $2.80 and sold $1,576,276 worth of shares (12,500 units at $126.10) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Product Officer Sakakibara Shan Riku exercised 4,000 shares at a strike of $29.82 and sold $1,000,000 worth of shares (8,000 units at $125.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 204,000 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChairman and CEO Atay Oguzhan exercised 26,250 shares at a strike of $2.80 and sold $4,729,379 worth of shares (38,750 units at $122.05) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDEROfficer Johnson Nancy Joann sold $100,056 worth of shares (801 units at $124.91) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 21,099 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSVP of Laboratory Operations Ten Bosch John Roderick sold $169,920 worth of shares (1,416 units at $120.00) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 33,552 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- SECBillionToOne Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - BillionToOne, Inc. (0002070849) (Filer)
- PRBillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed StudyTissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor types and two prospective cohortsMENLO PARK, Calif., June 29, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the publication of Longitudinal Methylated ctDNA Increases Predict Immunotherapy Progression Across Solid Tumors, a peer-reviewed study demonstrating that Northstar Response® was a stronger predictor of survival than standard-of-care imaging in patients with advanced solid tumors receiving immunotherapy or immunotherapy combination therapy,
- INSIDERChief Product Officer Sakakibara Shan Riku exercised 4,000 shares at a strike of $8.65 and sold $880,000 worth of shares (8,000 units at $110.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 208,000 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDEROfficer Ten Bosch John Roderick sold $287,363 worth of shares (2,832 units at $101.47) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 34,968 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Technology Officer Tsao David exercised 20,000 shares at a strike of $2.80 and sold $2,045,326 worth of shares (20,000 units at $102.27) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- SECBillionToOne Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - BillionToOne, Inc. (0002070849) (Filer)
- INSIDERDirector Bremner Thomas S was granted 3,017 shares, increasing direct ownership by 36% to 11,350 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERDirector Kolluri Krishna Kittu was granted 3,017 shares, increasing direct ownership by 36% to 11,350 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERDirector Ileri Firat was granted 3,017 shares, increasing direct ownership by 8% to 40,331 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERDirector Pagano Anthony was granted 3,017 shares, increasing direct ownership by 62% to 7,913 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERDirector Rai Akshay was granted 3,017 shares, increasing direct ownership by 27% to 14,026 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERLarge owner Neotribe Ventures I, L.P. acquired 14,828 shares and disposed of 450,779 shares (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERDirector Kolluri Krishna Kittu disposed of 450,779 shares and acquired 31,028 shares (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Product Officer Sakakibara Shan Riku sold $785,800 worth of shares (8,000 units at $98.22) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 212,000 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDEROfficer Johnson Nancy Joann sold $1,402,540 worth of shares (14,000 units at $100.18) as part of a pre-agreed trading plan, decreasing direct ownership by 39% to 21,900 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
BLLN FAQ
6 questionsWhere does BLLN stock trade?
BillionToOne Inc. (BLLN) is listed on NASDAQ.What sector and industry is BLLN in?
BillionToOne Inc. operates in the Health Care sector, Medical Specialities industry.When did BillionToOne Inc. go public?
BillionToOne Inc. (BLLN) completed its IPO in 2025.What are analysts saying about BLLN?
BillionToOne Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy on 2026-01-06.What companies are similar to BLLN?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare BLLN side-by-side with any of them on Quantisnow.How can I track BLLN on Quantisnow?
Quantisnow aggregates BillionToOne Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BLLN to receive live email and push alerts on every new disclosure.